Document is current
Any future updates will be listed below
-
Authors
Agustinus, Albert S. https://orcid.org/0000-0002-2700-6475
Al-Rawi, Duaa https://orcid.org/0000-0002-9218-6513
Dameracharla, Bhargavi
Raviram, Ramya
Jones, Bailey S. C. L. https://orcid.org/0000-0003-0007-2074
Stransky, Stephanie https://orcid.org/0000-0003-0844-2754
Scipioni, Lorenzo https://orcid.org/0000-0003-2980-1912
Luebeck, Jens https://orcid.org/0000-0003-4391-979X
Di Bona, Melody https://orcid.org/0000-0002-8853-2604
Norkunaite, Danguole
Myers, Robert M. https://orcid.org/0000-0003-1869-6467
Duran, Mercedes
Choi, Seongmin
Weigelt, Britta https://orcid.org/0000-0001-9927-1270
Yomtoubian, Shira
McPherson, Andrew
Toufektchan, Eléonore
Keuper, Kristina https://orcid.org/0000-0002-9841-5516
Mischel, Paul S. https://orcid.org/0000-0002-4560-2211
Mittal, Vivek https://orcid.org/0000-0002-4764-7413
Shah, Sohrab P. https://orcid.org/0000-0001-6402-523X
Maciejowski, John https://orcid.org/0000-0001-8134-9308
Storchova, Zuzana https://orcid.org/0000-0003-2376-7047
Gratton, Enrico
Ly, Peter https://orcid.org/0000-0001-8946-7069
Landau, Dan
Bakhoum, Mathieu F.
Koche, Richard P. https://orcid.org/0000-0002-6820-5083
Sidoli, Simone https://orcid.org/0000-0001-9073-6641
Bafna, Vineet https://orcid.org/0000-0002-5810-6241
David, Yael https://orcid.org/0000-0003-1696-0025
Bakhoum, Samuel F. https://orcid.org/0000-0002-4779-8422
- License Information
-
More Information
Article History
Received: 15 November 2021
Accepted: 14 April 2023
First Online: 7 June 2023
Change Date: 14 June 2023
Change Type: Update
Change Details: In the version of this article initially published, there was an error in the Peer review statement, which has now been amended.
Competing interests
: S.F.B. owns equity in, receives compensation from, serves as a consultant to, and serves on the scientific advisory board and board of directors of Volastra Therapeutics. V.B. is a co-founder, consultant, member of the scientific advisory board and has equity interest in Boundless Bio and Abterra. The terms of this arrangement have been reviewed and approved by the University of California, San Diego, in accordance with its conflict-of-interest policies. P.S.M. is a co-founder of Boundless Bio. He has equity in the company and chairs the scientific advisory board, for which he is compensated. B.W. reports a research grant from Repare Therapeutics, outside the submitted work. S.P.S. is a shareholder in Imagia Canexia Health and is a consultant with Astra Zeneca Inc, outside the submitted work, R.P.K. is a co-founder of and consultant for Econic Biosciences. The other authors declare no competing interests.
